RxDoctor Payments Data

Paul Harris, DO

Pulmonary Disease · Grand Rapids, MINPI 1033144266

Payments from drug & device makers

$20,073in general payments, 2019–2025

Across 40 payments — averaging $501.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$19K
  • Sanofi$167
  • GSK$106
  • Sanofi-aventis U.S. LLC$100
  • AstraZeneca$56
  • Boehringer Ingelheim$54
  • plus $178 from 8 others

What the payments were for

  • Travel & lodging$1,1746%
  • Food & beverage$7994%
  • Education$18,10090%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,073 in reported general payments places this provider in the 80th percentile of 463 pulmonary disease providers in Michigan.

See all pulmonary disease providers in Michigan

Medicare billing

Part B allowed, 2024
$47,540
Medicare patients
276
Services billed
748

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prolastin CAlpha-1-Proteinase Inhibitor17$250,923
Pirfenidone12$107,212
Breztri AerosphereBudesonide/Glycopyr/Formoterol134$97,767
Fasenra PenBenralizumab14$75,493
Trelegy ElliptaFluticasone/Umeclidin/Vilanter56$57,931
Spiriva RespimatTiotropium Bromide46$30,116
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate82$26,132
DuleraMometasone/Formoterol53$18,246
Spiriva HandihalerTiotropium Bromide13$17,106
Qvar RedihalerBeclomethasone Dipropionate55$15,546
BreynaBudesonide/Formoterol Fumarate45$14,764
Albuterol Sulfate HfaAlbuterol Sulfate273$10,943
SymbicortBudesonide/Formoterol Fumarate33$9,396
Breo ElliptaFluticasone/Vilanterol20$7,588
Bevespi AerosphereGlycopyrrolate/Formoterol Fum13$5,940

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCProlastin C$30$250,92317 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$56$113,104180 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$106$68,78189 claims
Boehringer IngelheimSpiriva Respimat$54$30,11646 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 463 pulmonary disease providers in Michigan.

Other pulmonary disease in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →